Stage IIIC Cutaneous Melanoma AJCC v7 Recruiting Phase 1 / 2 Trials for Dabrafenib (DB08912)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01989585Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment